ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast...